Wall Street expects a year-over-year increase in earnings on higher revenues when Hims & Hers Health, Inc. (HIMS) reports ...

Photo illustration of Wegovy and a weight scale. Wegovy is an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical ...

Hims & Hers is emerging as a disruptive force in the obesity treatment market, challenging established GLP-1 drug makers.

Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. ON THIS PAGE As a 37-year-old man who has seen ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform, has seen a steep decline recently, with its stock plunging 60% from February highs of over $70 to below $30. Long-term investors may find this ...

Results from a new survey of Hims & Hers’ employees has certified the company as a ‘great place to work’ for 2023 SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), ...

NEW YORK (Reuters) -Telehealth platform Hims & Hers will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy. A U.S.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Herc Holdings Inc (Symbol: HRI), where a total of 4,482 contracts have traded so far, ...

We're going to do a small debate here. The way this is going to work, Fools is that I am going to ask you to make your case first for Progeny, then for Hims & Hers. I'm going to ask you a follow up ...

Hims & Hers Health HIMS-3.85%decrease; red down pointing triangle said it is now providing menopause care, marking the company’s latest push into hormone-replacement therapies. The telehealth company ...